Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.61 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 8/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21825159 | 1.00 | GPR119 (0.61) | GPR119USP30MGLLALKCYP11B1 | |
| SCHEMBL3605978 | 0.93 | GPR119 (0.69) | GPR119MGLLALKEPHX2 | |
| SCHEMBL30324507 | 0.91 | GPR119 (0.54) | GPR119USP30MGLLALKEPHX2 | |
| SCHEMBL14861962 | 0.91 | GPR119 (0.54) | GPR119USP30MGLLALKEPHX2 | |
| SCHEMBL19023577 | 0.87 | GPR119 (0.51) | GPR119USP30MGLLALKEPHX2 | |
| SCHEMBL19023579 | 0.87 | GPR119 (0.51) | GPR119USP30MGLLALKEPHX2 | |
| SCHEMBL15050771 | 0.87 | GPR119 (0.64) | GPR119MGLLALKCYP11B1CYP11B2 | |
| SCHEMBL19023578 | 0.87 | GPR119 (0.51) | GPR119USP30MGLLALKEPHX2 | |
| SCHEMBL24117836 | 0.86 | GPR119 (0.79) | GPR119USP30ALK | |
| SCHEMBL5091205 | 0.86 | GPR119 (0.79) | GPR119USP30ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210392895-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LIMITED (IN) | 2021-12-23 | — | — | US | disclosed |
| US-20210392895-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LIMITED (IN) | 2021-12-23 | — | — | US | disclosed |
| WO-2020070610-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LTD. (IN) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210392895-A1 | NOVEL OXADIAZOLES | OXA1L, CYP1B1, CYP1A1 | GPR119 741/4885USP30 4128/4885MGLL 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.